<DOC>
	<DOC>NCT00321490</DOC>
	<brief_summary>This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.</brief_summary>
	<brief_title>Safety &amp; Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Patient has a documented clinical diagnosis of Major Depressive Disorder. Be able to understand and comply with the requirements of the study. Able to understand and provide written informed consent Patients (female) must not be pregnant or lactating Current or past diagnosis of stroke or transient ischemic attack (TIA).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>MDD</keyword>
	<keyword>Quetiapine fumarate, sustained release</keyword>
	<keyword>Depression</keyword>
</DOC>